Ryon P. Graf
YOU?
Author Swipe
View article: Supplementary Figure 4 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma
Supplementary Figure 4 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma Open
Supplementary Figure 4. Impact of ctDNA fraction on sensitivity of detection of PIK3CAmutations.
View article: Supplementary Figure 6 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma
Supplementary Figure 6 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma Open
Supplementary Figure 6. OTHERm variants show a range of subclonality andindependent oncogenicity
View article: Supplementary Figure 5 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma
Supplementary Figure 5 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma Open
Supplementary Figure 5. Comparison of performance of comprehensive genomicprofiling by next-generation sequencing (NGS) and PCR hotspot testing.
View article: Supplementary Figure 8 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma
Supplementary Figure 8 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma Open
Supplementary Figure 8. Overall survival among patients with PIK3CA-mutatedHR+HER2- breast cancer treated with alpelisib/fulvestrant versus fulvestrant alone.
View article: Supplementary Figure 3 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma
Supplementary Figure 3 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma Open
Supplementary Figure 3. PIK3CA variants detected in paired tissue and liquid samples.
View article: Supplementary Figure 9 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma
Supplementary Figure 9 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma Open
Supplementary Figure 9. Progression-free survival (PFS) among patients with SOLAR1mtreated with alpelisib+fulvestrant versus fulvestrant monotherapy.
View article: Supplementary Figure 7 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma
Supplementary Figure 7 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma Open
Supplementary Figure 7. Individual covariate balance before and after inverse probabilityof treatment weighting.
View article: Supplementary Figure 1 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma
Supplementary Figure 1 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma Open
Supplementary Figure 1. CONSORT diagram of genomic analyses cohorts
View article: Supplementary Figure 2 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma
Supplementary Figure 2 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma Open
Supplementary Figure 2. CONSORT diagrams for the cohorts with clinicogenomic data
View article: <i>LRP1b</i> Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial
<i>LRP1b</i> Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial Open
Purpose: Low-density lipoprotein receptor–related protein 1b (LRP1b) is a cell surface receptor, commonly altered in many cancers and associated with improved responses, progression-free survival (PFS), and overall survival with immune che…
View article: Supplementary Figure S3 from Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Supplementary Figure S3 from Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer Open
Outcomes on ARPI or taxane by CDK12alt status. Outcomes for CDK12alt vs. no CDK12alt are shown on ADT + ARPI for (A) TTCRPC and (C) OS. Outcomes for CDK12alt vs. no CDK12alt are shown on ADT + taxane for (B) TTCR and (D) OS. Abbreviations:…
View article: Data from Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Data from Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer Open
Purpose:Homologous recombination/DNA damage repair (HRR) alterations (HRRalt) are found in around 30% of patients with advanced prostate cancer and have been associated with worse prognosis in the metastatic castrate-resistant setting. How…
View article: Supplementary Figure S2 from Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Supplementary Figure S2 from Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer Open
Outcomes on ARPI or taxane by ATMalt status. Outcomes for ATMalt vs. no ATMalt are shown on ADT + ARPI for (A) TTCR and (C) OS. Outcomes for ATMalt vs. no ATMalt are shown on ADT + taxane for (B) TTCR and (D) OS. Abbreviations: aHR, adjust…
View article: Supplementary Figure S1 from Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Supplementary Figure S1 from Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer Open
Outcomes on ARPI or taxane by BRCAalt status. Outcomes for BRCAalt vs. no BRCAalt are shown on ADT + ARPI for (A) TTCR and (C) OS. Outcomes for BRCAalt vs. no BRCAalt are shown on ADT + taxane for (B) TTCR and (D) OS. Abbreviations: aHR, a…
View article: Correction: Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.
Correction: Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice. Open
View article: FoundationOne CDx and FoundationOne Heme Detect Epstein-Barr Virus with High Sensitivity and Specificity
FoundationOne CDx and FoundationOne Heme Detect Epstein-Barr Virus with High Sensitivity and Specificity Open
View article: Authors response to “Letter to the Editor”: “Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types”
Authors response to “Letter to the Editor”: “Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types” Open
View article: 15P Clinical relevance of tumor fraction assessment from circulating tumor DNA and RNF43 mutations as predictors of anti-BRAF/EGFR outcomes in metastatic colorectal cancer
15P Clinical relevance of tumor fraction assessment from circulating tumor DNA and RNF43 mutations as predictors of anti-BRAF/EGFR outcomes in metastatic colorectal cancer Open
View article: Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer Open
Purpose: Homologous recombination/DNA damage repair (HRR) alterations (HRRalt) are found in around 30% of patients with advanced prostate cancer and have been associated with worse prognosis in the metastatic castrate-resistant setting. Ho…
View article: Utility of plasma circulating DNA tumor fraction in bone-only metastatic breast cancer: a real-world outcomes study
Utility of plasma circulating DNA tumor fraction in bone-only metastatic breast cancer: a real-world outcomes study Open
Purpose Bone metastases develop in 50–70% of patients with metastatic breast cancer (MBC), with around one-third having bone as only site of distant disease (bone-only [BO]). Standard imaging is frequently insufficient to track bone metast…
View article: Clinical utility of companion diagnostic biomarker results below the limit of detection in comprehensive genomic profiling of patients with advanced non-small cell lung cancer
Clinical utility of companion diagnostic biomarker results below the limit of detection in comprehensive genomic profiling of patients with advanced non-small cell lung cancer Open
Background When the limit of blank (LoB) of comprehensive genomic profiling (CGP) for a given biomarker is acceptably demonstrated (ie, α ≤ 0.05 or LoB equal to zero), biomarkers detected below the assay limit of detection (LoD) can be rep…
View article: Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types Open
Background There is uncertainty around clinical applicability of tumor mutational burden (TMB) across cancer types, in part because of inconsistency between TMB measurements from different platforms. The KEYNOTE 158 trial supported United …
View article: Real world circulating tumor DNA detection in advanced pan-cancers by timing of liquid biopsy relative to therapy
Real world circulating tumor DNA detection in advanced pan-cancers by timing of liquid biopsy relative to therapy Open
View article: Data from Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice
Data from Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice Open
Purpose:The purpose of the study was to compare the effectiveness of PARP inhibitor maintenance therapy (mPARPi) in real-world practice by biomarker status [BRCA1/2 alterations (BRCAalt) and a homologous recombination deficie…
View article: Supplementary Tables and Figures 1 from Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice
Supplementary Tables and Figures 1 from Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice Open
Supplementary Tables and Figures
View article: Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study
Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study Open
View article: Pan-tumor validation of a NGS fraction-based MSI analysis as a predictor of response to Pembrolizumab
Pan-tumor validation of a NGS fraction-based MSI analysis as a predictor of response to Pembrolizumab Open
Microsatellite instability high (MSI-H) and mismatch repair deficient (dMMR) tumor status have been demonstrated to predict patient response to immunotherapies. We developed and validated a next-generation sequencing (NGS)-based companion …
View article: Data from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Data from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer Open
Purpose:Enzalutamide after abiraterone progression is commonly used in metastatic castration-resistant prostate cancer despite a low rate of clinical benefit. Analyzing IMbassador250, a phase III trial assessing enzalutamide with or withou…
View article: Supplementary Figure S11 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Supplementary Figure S11 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer Open
ctDNA TF response is more closely correlated with survival than PSA50 response in discordant cases
View article: Supplementary Figure S3 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Supplementary Figure S3 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer Open
ctDNA tumor fraction pre-enzalutamide to prognosticate overall survival and progression-free survival on enzalutamide post-abiraterone